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HbA1c are likely to lead to substantial clinical and economic benefits, driven by
reduced complication rates. The cost-effectiveness of interventions designed to
improve glycemic control in Saudi Arabia is worthy of investigation.
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OBJECTIVES:A1chieve is a prospective, international, observational study of basal,
bolus and biphasic insulin analogues in routine clinical practice. The present anal-
ysis aimed to evaluate the economic and clinical benefits associated with a 1%
reduction in HbA1c (relative to no change in HbA1c) in Malaysian A1chieve
patients. METHODS: Life expectancy, complication rate and the cost of complica-
tions were projected over a 35-year time horizon using the published CORE Diabe-
tes Model. At baseline, the mean (standard deviation) age of the cohort was 54 years
(11 years), duration of diabetes was 12 (8) years, HbA1c was 10% (1.8%) and body
mass index was 28.1 (5.1) kg/m2. HbA1c was reduced by 1%-point in the active
group versus the control group. Costs were reported in 2011 Malaysian Ringgits
(MYR) and converted to 2011 Euros (EUR) using the mid-market exchange rate on
June 30, 2011. Future costs and clinical outcomes were discounted annually at a
rate of 3.5%. RESULTS: A 1% reduction in HbA1c was associated with reduced costs
of treating diabetes complications and an increase in life expectancy. Undis-
counted life expectancy was improved by 0.36 years following HbA1c reduction
(7.53 versus 7.17 years). The time alive and free of any diabetes complications
increased from 0.31 years to 0.40 years in the HbA1creduction group. Over patient
lifetimes, improved HbA1c was associated with cost savings of EUR 682 [MYR 3,067]
(EUR 2,745 [MYR 13,607] versus EUR 3,427 [MYR 16,674]). The greatest cost savings
were associated with renal complications avoided. CONCLUSIONS: The A1chieve
study has shown that glycemic control is generally poor in routine clinical practice
in Malaysia. The present analysis showed that improved glycemic control would be
likely to bring substantial clinical and economic benefits to these patients, arising
primarily from reduced incidence of diabetes complications.
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OBJECTIVES: To estimate the long-term cost-effectiveness of adding twice-daily
exenatide (BID) to basal insulin in patients with type 2 diabetes from the perspec-
tive of NHS Scotland. Data from GWCO, a phase III, double-blind, randomized,
placebo-controlled trial, comparing the efficacy of adding exenatide BID to titrated
insulin glargine versus titrated insulin glargine alone, was used for the modelling
analysis. After 30 weeks, exenatide BID added to glargine was associated with
greater mean HbA1c reduction (-1.71% vs. -1.00%, p0.001) and weight reduction
(-1.78 kg vs. 0.96 kg, p0.001) compared to glargine alone. METHODS: A previ-
ously published and validated diabetes model (IMS CORE Diabetes Model) was used
to project 20-year clinical and cost outcomes based on the GWCO cohort (age 59
years, diabetes duration 12.3 years, HbA1c 8.41%) and efficacy and safety outcomes
from the GWCO trial. Costs were derived from published sources and expressed in
2011 Pounds Sterling (£). An annual discount rate of 3.5% was applied to future
costs and clinical benefits. RESULTS: In the base-case analysis exenatide BID plus
glargine was projected to improve quality-adjusted life expectancy by 0.183 qual-
ity-adjusted life years (QALYs) and life expectancy by 0.147 years compared to
glargine alone, at an additional cost of £1,721. The resulting cost per QALY was
£9,411. Increased pharmacy costs were partially offset by reduced costs associated
with diabetes complications with exenatide BID. Assuming a willingness-to-pay of
£20,000 per QALY gained, exenatide BID had a 99.8% probability of being cost-
effective. Sensitivity analyses showed that results were robust to variation in range
of model parameters. CONCLUSIONS: Based on results from GWCO clinical trial,
exenatide BID plus glargine is projected to be a cost-effective use of NHS Scotland
resources compared to glargine alone.
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OBJECTIVES: To assess cost-utility of switching type 2 diabetes patients to an in-
sulin detemir-based regimen after failure to achieve adequate control on 1) oral
antidiabetic agents (OADs) alone, or OAD in combination with 2) neutral protamine
Hagedorn (NPH) insulin, or 3) insulin glargine in Romania. METHODS: The CORE
Diabetes Model was used to model the long-term consequences. Efficacy results at
the beginning and at the end of the study as well as baseline demographics of the
patient cohort (subgroup analysis of the German cohort of PREDICTIVE study) were
used. The perspective was the health care services payer over life time (35-years).
The analysis used model default health state utility values. Cost data were derived
from DRG Data from the Center for Research and Evaluation of Healthcare Services
(Romania), CaNaMed National Catalogue of Medicines Prices (official tariff lists)
and expert opinion.RESULTS: In the 1st analysis (insulin detemirOADs vs. OADs)
QALYs increased by 0.399 years with insulin detemir. Total lifetime costs increased
by EUR 4,413 resulting in an incremental cost per QALY gained of EUR 11,050. In the
2nd analysis insulin detemir increased quality-adjusted life expectancy by 0.394
QALYs and total costs by EUR 2,340, with incremental cost per QALY gained of EUR
5,943. Transferring from insulin glargine  OADs to insulin detemir  OADs (3rd
analysis) increased QALYs by 0.319 years. Total costs increased by EUR 689 result-
ing in an incremental cost per QALY gained of EUR 2,160. CONCLUSIONS: Based on
efficacy data from an observational study and a validated health economics model,
insulin detemir was cost effective when compared to OAD alone, or insulin NPH 
OAD, or insulin glargine  OAD for the treatment of type 2 diabetes in the Roma-
nian health care setting.
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OBJECTIVES:Optimal glycemic control is a key goal in patients with type 2 diabetes
and is pivotal in reducing the risk of diabetes-related complications. The aim of the
present study was to investigate long-term clinical and economic benefits of a 1%
reduction in HbA1c versus baseline levels in patients enrolled in the A1chieve
study (an international, prospective, observational study of insulin use within rou-
tine clinical practice) in the Indonesian setting. METHODS: The analysis was per-
formed using the published and validated CORE Diabetes Model over a time hori-
zon of 35 years with future costs and clinical benefits were discounted at a rate of
3% per annum. At baseline patients had a mean HbA1c of 9.8%, the analysis com-
pared patients outcomes in which HbA1c remained at 9.8% in comparison with
reducing mean HbA1c by 1%; mean HbA1c was assumed to remain unchanged
throughout the simulation. Direct costs are presented in IDR (converted to EUR at a
rate of 1 EUR11,831 IDR). RESULTS: A 1% reduction in HbA1c from baseline led to
improvements in life expectancy and quality-adjusted life expectancy. Reducing
HbA1c from 9.8% to 8.8% improved life expectancy from 10.07 years to 10.69 years
(difference 0.61 years) and quality-adjusted life expectancy from 6.56 quality-ad-
justed life years (QALYs) to 7.04 QALYs (difference 0.48 QALYs). Mean direct costs
were also IDR 6,403,196 (EUR 541) lower in the reduced HbA1c group (IDR
242,721,221 [EUR 20,551] versus IDR 236,318,025 [EUR 20,026]), with the biggest
driver of cost savings being the reduced incidence of renal complications in the
reduced HbA1c group. CONCLUSIONS: Baseline glycemic control in patients with
diabetes in the Indonesian setting was sub-optimal; however, a 1% reduction in
HbA1c from baseline was associated with improved life expectancy and quality-
adjusted life expectancy as well as being cost-saving over a 35-year time horizon.
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INTRODUCTION: In T2DM, HbA1c tends to drift up over time and the extent to
which anti-hyperglycemic agents can maintain initial glucose lowering effect (or
durability) varies. HbA1c evolution is an important determinant of future outcomes
and costs. Currently there is no consensus on how to model upward drift in HbA1c
or the durability of treatments. OBJECTIVES: Review different approaches to mod-
eling HbA1c evolution and assess their impact on economic evaluations of T2DM
interventions. METHODS: We reviewed the ways in which HbA1c evolution has
been modeled. Lifetime simulations were performed that compared two hypothet-
ical treatments: 1) initial HbA1c reduction of 1.25% and annual cost of $1,000 and 2)
initial HbA1c reduction of 1% and annual cost of $200, using ECHO-T2DM, a vali-
dated micro-simulation model. . Treatment was intensified in both arms when
HbA1c exceeded 7.0%, first by adding basal insulin and subsequently by adding 3x
daily short-acting insulin. RESULTS: Four different approaches were identified: (1)
no HbA1c evolution; (2) constant increase in HbA1c, irrespective of treatment; (3)
constant treatment-specific increase in HbA1c; and (4) non-linear increase in
HbA1c, irrespective of treatment. The simulations confirmed that these assump-
tions are critical. While the incremental life-years (LY’s) and Quality-Adjusted LYs
(QALYs) were similar in the first 3 scenarios, the absolute values were highest for
(1). Cost-savings and QALY gains were largest in (3), which allowed HbA1c to drift
apart over time in each arm, and smallest in (2) (because treatment intensification
reduced the HbA1c gap). The incremental cost-effectiveness ratio (ICER) ranged
from $3,196 in (3) to $32,444 in (2). (4) could not be implemented in this version of
ECHO-T2DM. CONCLUSIONS: Assumptions used to model HbA1c evolution have
important consequences for estimates of cost-effectiveness, a 10-fold difference in
the ICER in this hypothetical example, and should be addressed with sensitivity
analysis in health economic evaluations.
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OBJECTIVES: To investigate the economic benefits of a 1% reduction in HbA1c in
comparison with baseline levels in patients with type 2 diabetes in Algeria enrolled
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in the A1cheive study. METHODS: The CORE Diabetes Model was used to make
long-term projections of clinical and cost outcomes associated with a 1% HbA1c
reduction based on A1chieve, a global, prospective, observational study of basal,
mealtime and biphasic insulin analogs in routine clinical practice. At baseline,
mean (SD) patient age was 60 (10) years, duration of diabetes 12 (5) years and HbA1c
9.2 (1.8)%. HbA1c was reduced by 1%-point from baseline in the active group rela-
tive to the control group. Life expectancy, complication rates and the cost of com-
plications were projected of a 35-year time horizon. Future costs and clinical out-
comes were discounted at 3% annually. Costs are presented in 2011 Algerian Dinar
(DZD), converted to Euros (EUR) at an exchange rate of DZD 1:EUR 0.096. RESULTS:
A 1% reduction in HbA1c was associated with improvements in both clinical and
economic outcomes. Undiscounted life expectancy was improved by 0.17 year with
a 1% improvement in HbA1c (6.58 versus 6.40 years). The cumulative incidence of
all diabetes related complications included in the analysis was lower in the 1%
HbA1c reduction group. Complication costs were DZD 9,669 (EUR 93) lower fol-
lowing HbA1c reduction (DZD 387,236 [EUR 3,717] versus DZD 396,905 [EUR
3810]). The most pronounced difference was in the cost of renal complications.
CONCLUSIONS:Glycemic control in A1chieve patients was generally suboptimal in
the Algerian setting. Improvements in glycemic control are likely to lead to sub-
stantial clinical and economic benefits due to reduced complication rates. Conse-
quently, the cost-effectiveness of intensifying treatment in these patients is wor-
thy of further analysis.
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OBJECTIVES: Diabetes represents a huge health care challenge for India. Estimates
suggest that there are over 61 million people living with diabetes in India (preva-
lence of 9.2% in adults), and diabetes caused approximately 983,000 deaths in 2011.
The aim of this study was to evaluate the benefits in long-term clinical and cost
outcomes associated with improving glycemic control in type 2 diabetes patients in
India. METHODS: Cohort characteristics were based on Indian patients in
A1chieve, a global, observational, prospective study of insulin analogs in daily
clinical practice. At baseline, patients had a mean (standard deviation) age of 51.8
(10.1) years, duration of diabetes of 6 (4.6) years and glycated hemoglobin (HbA1c) of
8.3% (1.4%). A published and validated model of type 2 diabetes (CORE Diabetes
Model) was used to make long-term projections of clinical outcomes and direct
costs (2011 Indian Rupees [INR], converted to Euros [EUR] at INR 0.015EUR 1).
Future costs and clinical benefits were discounted at 3% annually. RESULTS: Over
a 35-year time horizon, reducing HbA1c by 1% was projected to improve mean life
expectancy by 0.64 years (10.95 versus 11.59 years) and quality-adjusted life expec-
tancy by 0.53 QALYs (7.36 versus 7.89 QALYs). Benefits were driven by lower com-
plication rates with improved glycemic control. End-stage complications such as
myocardial infarction, end-stage renal disease, severe vision loss and lower limb
amputation were reduced by 4%, 46%, 33% and 3%, respectively (relative risk).
Direct costs were reduced by INR 33,443 (EUR 502) due to complications avoided
control (INR 256,101 [EUR 3,842] versus INR 222,659 [EUR 3,340]). CONCLUSIONS:
HbA1c levels are above guideline targets in India. Improving glycemic control is
likely to substantially lower the risk of complications, improve survival and reduce
complication costs. Cost-effectiveness analyses of interventions/management
programs designed to improve glycemic control are merited for the Indian setting.
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OBJECTIVES: Evaluate the cost-utility (CUA) of vildagliptin or sulphonylurea as add
on to metformin treatment for DMII patients for the Greek NHS METHODS: A
validated patient level simulation model was used based on UKPDS risk equations
(Clarke 2004) to estimate long run micro/macro-vascular complications and mor-
tality over a lifetime horizon. During each cycle a patient can experience different
complications: ischemic heart disease, myocardial infarction (MI), chronic heart
failure, renal failure, stroke, amputation, blindness in one eye. The outcomes as-
sessment criteria were Quality Adjusted Life Years (QALYs) and Life Years Gained
(LYG). Quality of life decrements were derived from literature. Discount rates of
3.5% were set for both costs and outcomes and univariate sensitive analysis was
conducted. Drug costs were based on Greek published list prices 2012, while com-
plication cost was obtained from International literature. RESULTS: The mean
number of QALYs per patient in the lifetime horizon was 6.24 in the
vildagliptin&metformin group and 6.16 in sulphonylurea&metformin group, re-
sulting in 0.08 QALYs in favor of vildagliptin&metformin group. Total costs per
patient were €7,848 in vildagliptin&metformin group and €7,572 for
sulphonylurea&metformin, resulting in €276 cost difference for the latter. The in-
cremental cost effectiveness ratio (ICER) for vildagliptin&metformin versus
sulfonylurea&metformin is estimated at €3.371 per QALY for a lifetime horizon.
Regarding the analysis on life years gained, vildagliptin&metformin group had on
average 8,01 LYG and sulphonylurea&metformin 7,93, leading to a difference of
0.08 years in favour of vildagliptin&metformin. ICER for vildagliptin&metformin
versus sulfonylurea&metformin is estimated at €3.424 per life years gained.
CONCLUSIONS: For the Greek NHS adding Vildagliptin to Metformin is projected to
be highly cost-effective for patients with type 2 diabetes who are not at HbA1C goal
on Metformin compared to adding SU to Metformin. The price difference of the two
comparators is bridged when complications’ cost is included in the analysis.
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OBJECTIVES: Achieving glycemic control forms the cornerstone of type 2 diabetes
management and is key in reducing diabetes-related complications. The aim of the
current analysis was to investigate the long-term clinical and economic benefits of
a 1% reduction in HbA1c in comparison with baseline levels for type 2 diabetes
patients enrolled in the A1chieve study (an international, prospective, observa-
tional study of insulin analogs within routine clinical practice) in the Mexican
setting. METHODS: The analysis was performed using the published and validated
CORE Diabetes Model, over a 35-year time horizon, with future costs and clinical
outcomes discounted at a rate of 3% per annum. At baseline, mean (SD) patient age
was 55(13) years, duration of diabetes 11(7.5) years and HbA1c 10.3(2.2)%. An HbA1c
reduction of 1% was applied in the active arm, after which it was assumed that
HbA1c remained constant. Captured costs included diabetes-related complications
and concomitant medications. Costs of antihyperglycemic treatment and adverse
events were not included. Costs are presented in 2011 Mexican Pesos (MXN) and
converted into Euros (EUR) (MXN 1 to EUR 0.058). RESULTS: A 1% reduction in
HbA1c was associated with increased life expectancy of 0.51 years (8.70 years ver-
sus 8.19 years) and reduced cumulative incidence of all modelled diabetes-related
complications. Total mean direct costs were MXN 41,875 (EUR 2,429) lower in pa-
tients with HbA1c of 9.3% versus those with HbA1c remaining at 10.3% (MXN
596,985 [EUR 34,625] versus MXN 638,860 [EUR 37,054]). This was driven by savings
from the reduced incidence of complications. CONCLUSIONS: Baseline glycemic
control in A1chieve type 2 diabetes patients in the Mexican setting was generally
poor. Even modest improvements in HbA1c are likely to lead to substantial clinical
and economic benefits, due to reduced complication rates. Consequently, the cost-
effectiveness of intensifying treatment is worthy of further analyses.
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OBJECTIVES: Vildagliptin has demonstrated efficacy on HbA1c comparable to
glimepiride after 2 years of add-on treatment to metformin with markedly reduced
hypoglycemic risk. The current analysis aims to assess the add-on of vildagliptin
versus generic sulphonylureas (SUs) to metformin using a cost-effectiveness anal-
ysis (CEA) framework from the Portuguese societal perspective. Whilst generic SUs
have a lower acquisition price, hypoglycemic events represent a significant eco-
nomic burden and therefore the CEA framework can contribute to better
decision-making. METHODS: The CEA utilized a patient level simulation model
building on the UKPDS risk equations to estimate micro/macro-vascular complica-
tions and mortality over a lifetime horizon. Clinical parameters in the current
model include: HbA1c levels, weight gain, systolic blood pressure, total cholesterol,
HDL and incidence of hypoglycemic events. Patient distribution on demographic
and clinical variables was based on Portuguese epidemiological data. The treat-
ment algorithm allows for treatment switch when: HbA1c goal is not met; drug
intolerance; poor compliance. Drug parameters and quality of life decrements were
derived from literature. Drug costs were based on Portuguese list prices, while the
unit cost of each complication was obtained from the Diagnosis Related Groups
tariff. RESULTS: On average, the add-on of vildagliptin was estimated to result in a
per patient gain of 0.11 QALY and an increase of €1,453 on total cost when com-
pared to the add-on of SU to metformin, resulting in an incremental cost-effective-
ness ratio of €12,794/QALY.CONCLUSIONS:Under the Portuguese societal perspec-
tive, adding vildagliptin is projected to be likely cost-effective for patients with type
2 diabetes who are not at HbA1c goal on metformin compared with adding generic
SUs.
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OBJECTIVES: Despite the growing incidence of diabetes, the occurrence of compli-
cations requiring hospitalization has stabilized in the last decade. Advances in
health care and improved access to innovative drugs may have led to these health
gains. We aimed to explore the relationship between patients’ access to newer oral
anti-diabetic drugs (OADs) and the number and costs of hospitalizations attribut-
able to diabetes. METHODS: For the period 2000-2009, we collected data on: 1) the
number of hospital admissions and their costs attributable to diabetes; 2) the num-
ber of patients treated for diabetes per year and health region, based on the OADs
consumption (treated prevalence); and 3) the evolution of the average vintage
A501V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 2 7 7 – A 5 7 5
